UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 25

 

 

NOTIFICATION OF REMOVAL FROM LISTING

AND/OR REGISTRATION UNDER SECTION 12(b)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 000-50549

Issuer: Oncternal Therapeutics, Inc.

 

 

Exchange: The Nasdaq Stock Market, LLC

(Exact name of Issuer as specified in its charter, and name of Exchange

where security is listed and/or registered)

 

 

Address:12230 El Camino Real

Suite 230

San Diego, CA 92130

Telephone number: (858) 434-1113

(Address, including zip code, and telephone number, including area code, of Issuer’s principal executive offices)

Common Stock, par value $0.001 per share

(Description of class of securities)

 

 

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

 

☐

17 CFR 240.12d2-2(a)(1)

 

☐

17 CFR 240.12d2-2(a)(2)

 

☐

17 CFR 240.12d2-2(a)(3)

 

☐

17 CFR 240.12d2-2(a)(4)

 

☐

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1

 

☒

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements for the Securities Exchange Act of 1934, Oncternal Therapeutics, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

 

March 17, 2025				By		Chase Leavitt				General Counsel
Date						Name				Title

 

1	Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.